Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
ConclusionThis is the first report of “real-world” data on ICI in relapsed SCLC also including patients with poor PS. Promising durable responses were observed. No biological prognostic marker could be identified.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Immunotherapy | Lung Cancer | Small Cell Lung Cancer | Switzerland Health | Yervoy